Cargando…
Dynamic coagulofibrinolytic responses under long-term VV-ECMO management without anticoagulation in a COVID-19-ARDS patient: A case report
Venovenous extracorporeal membrane oxygenation (ECMO) is recommended for the treatment of critically ill patients with acute respiratory distress syndrome due to coronavirus disease 2019 (COVID-19). However, ECMO management can cause both bleeding and thrombotic complications. There are insufficient...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875986/ https://www.ncbi.nlm.nih.gov/pubmed/36705388 http://dx.doi.org/10.1097/MD.0000000000032817 |
_version_ | 1784878068599357440 |
---|---|
author | Matsumoto, Hironori Kikuchi, Satoshi Murata, Satoru Ohshita, Muneaki Harima, Yutaka Annen, Suguru Mukai, Naoki Nakabayashi, Yuki Ogawa, Shirou Okita, Mitsuo Takeba, Jun Sato, Norio |
author_facet | Matsumoto, Hironori Kikuchi, Satoshi Murata, Satoru Ohshita, Muneaki Harima, Yutaka Annen, Suguru Mukai, Naoki Nakabayashi, Yuki Ogawa, Shirou Okita, Mitsuo Takeba, Jun Sato, Norio |
author_sort | Matsumoto, Hironori |
collection | PubMed |
description | Venovenous extracorporeal membrane oxygenation (ECMO) is recommended for the treatment of critically ill patients with acute respiratory distress syndrome due to coronavirus disease 2019 (COVID-19). However, ECMO management can cause both bleeding and thrombotic complications. There are insufficient coagulofibrinolytic data for appropriate ECMO management in patients with COVID-19. PATIENT CONCERNS: A 48-year-old man with severe COVID-19-acute respiratory distress syndrome underwent long-term venovenous ECMO management for 48 days. Refractory oronasal bleeding developed on day 13, so the administration of unfractionated heparin was ceased for 29 days. DIAGNOSIS: The patient showed dynamic coagulofibrinolytic responses associated with ECMO management, as shown by fibrin/fibrinogen degradation products, soluble fibrin, thrombin-antithrombin complex, and plasmin-α(2)-plasmin inhibitor complex elevations, suggesting the development of ECMO-induced coagulopathy. INTERVENTIONS: We assessed coagulofibrinolytic markers to decide the appropriate timing for controlling excessive activation of coagulation by exchanging ECMO circuits. Moreover, viscoelastic hemostatic assays were used for adequate transfusion of blood products. OUTCOMES: Safe long-term ECMO management was completed, which was withdrawn on day 48. The patient was weaned off mechanical ventilation on day 57 and was transferred to another hospital for rehabilitation. LESSONS: Monitoring the coagulofibrinolytic status using markers and viscoelastic hemostatic assays may be effective for safe long-term ECMO management even without anticoagulant therapy. |
format | Online Article Text |
id | pubmed-9875986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-98759862023-01-27 Dynamic coagulofibrinolytic responses under long-term VV-ECMO management without anticoagulation in a COVID-19-ARDS patient: A case report Matsumoto, Hironori Kikuchi, Satoshi Murata, Satoru Ohshita, Muneaki Harima, Yutaka Annen, Suguru Mukai, Naoki Nakabayashi, Yuki Ogawa, Shirou Okita, Mitsuo Takeba, Jun Sato, Norio Medicine (Baltimore) 3900 Venovenous extracorporeal membrane oxygenation (ECMO) is recommended for the treatment of critically ill patients with acute respiratory distress syndrome due to coronavirus disease 2019 (COVID-19). However, ECMO management can cause both bleeding and thrombotic complications. There are insufficient coagulofibrinolytic data for appropriate ECMO management in patients with COVID-19. PATIENT CONCERNS: A 48-year-old man with severe COVID-19-acute respiratory distress syndrome underwent long-term venovenous ECMO management for 48 days. Refractory oronasal bleeding developed on day 13, so the administration of unfractionated heparin was ceased for 29 days. DIAGNOSIS: The patient showed dynamic coagulofibrinolytic responses associated with ECMO management, as shown by fibrin/fibrinogen degradation products, soluble fibrin, thrombin-antithrombin complex, and plasmin-α(2)-plasmin inhibitor complex elevations, suggesting the development of ECMO-induced coagulopathy. INTERVENTIONS: We assessed coagulofibrinolytic markers to decide the appropriate timing for controlling excessive activation of coagulation by exchanging ECMO circuits. Moreover, viscoelastic hemostatic assays were used for adequate transfusion of blood products. OUTCOMES: Safe long-term ECMO management was completed, which was withdrawn on day 48. The patient was weaned off mechanical ventilation on day 57 and was transferred to another hospital for rehabilitation. LESSONS: Monitoring the coagulofibrinolytic status using markers and viscoelastic hemostatic assays may be effective for safe long-term ECMO management even without anticoagulant therapy. Lippincott Williams & Wilkins 2023-01-27 /pmc/articles/PMC9875986/ /pubmed/36705388 http://dx.doi.org/10.1097/MD.0000000000032817 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 3900 Matsumoto, Hironori Kikuchi, Satoshi Murata, Satoru Ohshita, Muneaki Harima, Yutaka Annen, Suguru Mukai, Naoki Nakabayashi, Yuki Ogawa, Shirou Okita, Mitsuo Takeba, Jun Sato, Norio Dynamic coagulofibrinolytic responses under long-term VV-ECMO management without anticoagulation in a COVID-19-ARDS patient: A case report |
title | Dynamic coagulofibrinolytic responses under long-term VV-ECMO management without anticoagulation in a COVID-19-ARDS patient: A case report |
title_full | Dynamic coagulofibrinolytic responses under long-term VV-ECMO management without anticoagulation in a COVID-19-ARDS patient: A case report |
title_fullStr | Dynamic coagulofibrinolytic responses under long-term VV-ECMO management without anticoagulation in a COVID-19-ARDS patient: A case report |
title_full_unstemmed | Dynamic coagulofibrinolytic responses under long-term VV-ECMO management without anticoagulation in a COVID-19-ARDS patient: A case report |
title_short | Dynamic coagulofibrinolytic responses under long-term VV-ECMO management without anticoagulation in a COVID-19-ARDS patient: A case report |
title_sort | dynamic coagulofibrinolytic responses under long-term vv-ecmo management without anticoagulation in a covid-19-ards patient: a case report |
topic | 3900 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875986/ https://www.ncbi.nlm.nih.gov/pubmed/36705388 http://dx.doi.org/10.1097/MD.0000000000032817 |
work_keys_str_mv | AT matsumotohironori dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT kikuchisatoshi dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT muratasatoru dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT ohshitamuneaki dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT harimayutaka dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT annensuguru dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT mukainaoki dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT nakabayashiyuki dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT ogawashirou dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT okitamitsuo dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT takebajun dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport AT satonorio dynamiccoagulofibrinolyticresponsesunderlongtermvvecmomanagementwithoutanticoagulationinacovid19ardspatientacasereport |